Ciechanover Sells 6000 Shares of Atara Biotherapeutics Inc. (ATRA) Stock

Jeannie Matthews
January 14, 2018

The Company's deposit products include savings, checking, interest-bearing checking, money market deposit, and certificate of deposit accounts, as well as IRA and KEOGH accounts. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. (NASDAQ:ATRA) has "Neutral" rating given on Wednesday, November 18 by Goldman Sachs. A significant increase in trading volume means that more than double the average amount of stocks are moving.

Traders have different rules for what constitutes liquidity and a good guide is the volume of trades and volume of shares that are traded each day.

Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 8,600 shares of the business's stock in a transaction on Wednesday, January 10th. The share price volatility of the stock remained at 6.86% for the month and by reducing the timeframe to just a week, the volatility stood at 7.22%. We have $23.27 PT which if reached, will make NASDAQ:ATRA worth $40.29M more. After a recent check, Atara Biotherapeutics, Inc. Atara now has six drugs in various stages of development, including treatments for blood cancers, solid tumors, autoimmune conditions and infectious diseases. It now has negative earnings.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Thursday, November 9th. Therefore 67% are positive.

Analysts await Atara Biotherapeutics, Inc. The firm has "Neutral" rating given on Wednesday, January 3 by Citigroup. The rating was maintained by Citigroup with "Sell" on Friday, August 19.

Florida officers wrangle 12.5-foot python
Late Thursday night officer Joseph Cabrera took down a 12.5-foot Burmese python that was slithering around in the southern part of the state.

Mizuho Reaffirms Buy Rating for Cypress Semiconductor Corp. (CY)
It has outperformed by 54.06% the S&P500. 263.89 million shares or 3.63% more from 254.64 million shares in 2017Q2 were reported. Analysts have placed a $18.35 price target on Cypress Semiconductor Corporation, suggesting a 8.77% gain from recent close.

FedEx (NYSE:FDX) Price Target Raised to $293.00
Selway Asset Management decreased its stake in Fedex (FDX) by 28.17% based on its latest 2017Q3 regulatory filing with the SEC. Stephens set a $306.00 price target on FedEx and gave the stock a "buy" rating in a research note on Wednesday, December 20th.

Several analysts recently commented on ATRA shares. The stock has "Outperform" rating by William Blair on Friday, October 9. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Friday, September 15. As per Tuesday, December 15, the company rating was maintained by JMP Securities. The firm earned "Buy" rating on Thursday, June 22 by Jefferies.

Since August 10, 2017, it had 0 buys, and 14 selling transactions for $999,963 activity. 6,000 shares were sold by Haqq Christopher, worth $91,800. Company insiders own 16.20% of the company's stock. MCGRATH JOHN sold $60,102 worth of stock. Clark Mitchall G. had sold 3,021 shares worth $43,291 on Tuesday, August 15. It improved, as 8 investors sold Atara Biotherapeutics, Inc. shares while 16 reduced holdings. For the quarter, shares are performing at 90.88%. After $-1.02 actual EPS reported by Atara Biotherapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.76% negative EPS growth. If RVOL is less than 1 it is not In Play on this trading day and Investors may decide not to trade it. Its up 0.26, from 1.28 in 2017Q2. The Manufacturers Life Insurance Company lifted its position in Atara Biotherapeutics by 7.2% during the 2nd quarter. 9 funds opened positions while 28 raised stakes. Bridger Limited Liability Corporation invested in 1.64% or 1.65M shares. Chase Inv Counsel, a Virginia-based fund reported 53,904 shares.

4,591 are owned by Bank Of Montreal Can. Barclays Public has invested 0% of its portfolio in Atara Biotherapeutics, Inc. Trexquant Limited Partnership holds 0.13% or 5,600 shares. Lpl Fin Ltd Llc owns 76,539 shares for 0.01% of their portfolio. American Intl Gru holds 48,001 shares or 0.02% of its portfolio. Great West Life Assurance Can invested in 1,654 shares or 0% of the stock. Schwab Charles Investment Mngmt accumulated 0.02% or 732,165 shares. Canaccord Genuity initiated the stock with "Buy" rating in Wednesday, September 9 report. Approximately 795,600 shares were traded during trading, a decline of 34% from the average daily volume of 1,212,243 shares. Credit Suisse Ag has 0% invested in Atara Biotherapeutics, Inc.

Dalton Greiner Hartman Maher & Co holds 1.19% of its portfolio in Provident Financial Services, Inc. for 797,900 shares. (NYSE:MTOR). Vanguard Group Inc Inc has 0.01% invested in Meritor, Inc. Alpha Windward Llc, a Massachusetts-based fund reported 18,960 shares. They expect $0.38 earnings per share, up 8.57% or $0.03 from last year's $0.35 per share. MTOR's profit would be $41.64M giving it 12.64 P/E if the $0.47 EPS is correct. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.97) by ($0.05). analysts predict that Atara Biotherapeutics Inc will post -4 EPS for the current year. If a stock does not have good liquidity then it may take some time before a broker is able to negotiate a deal to buy or sell a stock and the broker may not be able to get the sell or buy price that the trader is looking for. About 141,769 shares traded. It is down 27.93% since January 13, 2017 and is uptrending. It has outperformed by 4.92% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Other reports by

Discuss This Article

FOLLOW OUR NEWSPAPER